Phase 1 N=52 Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
Lupus Erythematosus · Lupus Nephritis
Primary: Number of Treatment Emergent Adverse Events — 0; 17; 2; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia
Insomnia Disorder · Nocturia
Primary: Change From Baseline to Week 4 in sTST — 56.6; 35.7 minutes — p=0.002
N/A N=29 IMAGINATOR 2.0: Co-design and Early Evaluation of a Novel Blended Digital Intervention Targeting Self-harm in Young People
Self Injurious Behavior · Adolescent Behavior Problem · Child Behavior Problem
Primary: Number of Patients Lost to Attrition — 14 Participants
Phase 2 N=16 Semaglutide Use in Elderly Obese Patients
Obesity · Aging
Primary: Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio — 1.04; 1.0; 0.96; 0.99 Arbitrary units (ratio)
Phase 1 N=29 Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
B-cell Non Hodgkin Lymphoma · Advanced Solid Tumor
Primary: To Determine, During the Dose Escalation Phase, the Recommended Dose of PCLX-001 for the Dose Expansion Phase of the Trial. — 210 mg
N/A N=163 Effect of Emotion Mindsets on Emotion Processing
Emotions
Primary: Mean Change From Pre to Post Mindset Manipulation on Emotion Mindset Scale (Measures Beliefs About Whether Emotions Are Fixed or Malleable) — 3.03; 3.03; 2.17; 2.76…
N/A N=2,108 Providers Against Cavities in Children's Teeth
Dental Caries
Primary: Dental Attendance — 330; 332; 170; 150 Participants
N/A N=101 Delivering Health: Addressing Diabetes and Food Insecurity
Food Insecurity · Diabetes Mellitus, Type 2
Primary: Hemoglobin A1c (HbA1c), % — 9.87; 9.12 percentage of glycosylated hemoglobin — p=0.0107
Phase 3 N=166 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Chronic Lymphocytic Leukemia (CLL)
Primary: Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS) — 81.3; 54.7 percentage of participants — p=0.0004
N/A N=36 What is the Efficiency When Comparing Active Sentry at Low IOP vs Ozil at High IOP?
Cataract
Primary: Total Aspiration Time — 90.1; 85.1 seconds
Phase 2 N=100 Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
Chemotherapy-induced Nausea and Vomiting
Primary: Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3…
N/A N=97 Second Generation LMA Versus Endotracheal Tube in Obese Patients
Obese · Endotracheal Tube · Laryngeal Mask Airway
Primary: Proportion of Participants With Postoperative Hypoxia — 54.2; 34.7 percentage of participants
N/A N=21 Targeting Personalized Brain States Reflecting Strong and Weak Corticospinal Tract Output in Real-time
Neurotypical Adults
Primary: Motor-evoked Potential (MEP) Amplitudes — 1.13; 0.96; 0.90 arbitrary units (normalized microvolts)
N/A N=17 Hearing Aid and Individuals With Cognitive Disorders
Presbycusis, Bilateral · Alzheimer Disease 2 Due to Apoe4 Isoform · Mild Cognitive Impairment
Primary: Hearing Aid Benefit as Measured by the International Outcomes Inventory for Hearing Aids (IOI-HA) — 3.9; 3.4; 3.7 score on a scale
N/A N=159 Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
Cognition
Primary: Relationship Between Prefrontal Cortex Activation and Respiratory Sinus Arrhythmia — -0.064; 0.00375 Micro mol per second — p=0.008